A colony-forming assay for human tumour xenografts using agar in diffusion chambers. by Smith, I. E. et al.
Br. J. Cancer (1976) 34, 476.
A COLONY-FORMING ASSAY FOR HUMAN TUMOUR XENOGRAFTS
USING AGAR IN DIFFUSION CHAMBERS
I. E. SAMITH, V. D. COURTENAY AND A. Y. GORDON
Fromn the Department of Biophysics, Institute of Cancer Research, Sutton, Surrey
Received 30 April 1976 Accepted 28 June 1976
Summary.-A technique for growing colonies from single-cell suspensions of human
tumour xenografts using agar in diffusion chambers is described. Modified Milli-
pore diffusion chambers containing tumour cells in semi-solid agar-medium were
implanted into the peritoneal cavity of pre-irradiated mice and provided standard
culture conditions for the study of colony-forming cells. All 11 xenograft tumours
so far studied produced colonies. The incubation period for colony growth ranged
from 12 to 28 days and the plating efficiency ranged from 0.30/ to 16% for different
tumours, but both parameters were constant for each individual tumour.
The reproducibility of the system provides a colony-forming assay which can be
used to study the effects of irradiation and cytotoxic drugs on human tumour clono-
genic cells and may therefore have some advantages over similar assays based on
experimental animal tumours.
THE application to clinical cancer
therapy of laboratory studies on the
effects ofcytotoxic agents has been greatly
restricted by the profound differences
which exist between experimental animal
tumours and tumours in man. The
recent development of techniques for
propagating human tumour xenografts in
immune-deprived mice offers the possi-
bility ofan experimental model that might
more closely mimic the response to therapy
of human cancers, and studies on the
effects of cytotoxic drugs on human
tumour xenografts have already been
published (Cobb and Mitchley, 1974;
Rygaard and Povlsen, 1974; Kopper and
Steel, 1975; Povlsen and Jacobsen, 1975).
A colony-forming assay for tumour cells
from xenografts, similar to those already
described for experimental animal
tumours (Park, Bergsagel and McCulloch,
1971; Thomson and Rauth, 1974; Courte-
nay, 1976), would allow more specific
information on cellular sensitivity to be
determined, and might permit the demon-
stration of resistant clones of cells hinder-
ing clinical response to treatment.
An assay using agar in diffusion
chambers for colony-forming cells from
human bone marrow has already been
reported (Gordon, Blackett and Douglas,
1975). This paper describes an adapta-
tion of this assay for the study of colony-
forming cells from human tumour xeno-
grafts grown in immune-deprived mice.
METHODS
Human tumour xenografts.-The xeno-
giafts used in this study were grown from
human tumour biopsy material inoculated
into the thigh muscles or flank subcutaneous
tissue of syngeneic CBA/lac mice, immune-
suppressed by thymectomy, whole body
irradiation and marrow transplantation, as
described by Pickard, Cobb and Steel (1975).
Details of the original tumours and their
histological type are given in the Table.
Further details of the histology, growth rate
and kinetics of 3 of the xenografts (HX12,
HX18, HX29) have been previously de-
scribed (Pickard et al., 1975; Kopper and
Steel, 1975).
Cell suspensions.-Tumours excised from
mice freshly killed by neck dislocation were
w,ashed and finely chopped in phosphate-TUMOUR CELL COLONIES IN AGAR DIFFUSION CHAMBERS
buffered saline (PBS) using a crossed-scalpel
technique. Further treatment to produce
a viable single-cell suspension was then
determined empirically for each tumour and
details are shown in the Table. Some xeno-
grafts required only incubation in PBS at
37°C for 15 min; some required incubation
with trypsin 1: 100 in PBS for between 5 and
10 min; one (pancreatic carcinoma xenograft
HX32) required incubation in collagenase
2 mg/ml in Ham's medium with 15% foetal
calf serum for 30 min, followed by trypsin
1: 100 in PBS for a further 5 min, after
washing free of serum. All cell suspensions
were finally filtered (Simon Polyester Mesh,
aperture 30 ,tm) and a single-cell suspension
obtained in ice-cold Ham's medium and 15%
foetal calf serum. Viability was assessed by
dye exclusion using lissamine green. Dif-
fusion chambers were then filled with the
required number of cells for assay, suspended
in Ham's medium, serum and 0 3% agar.
Filling and implantation of agar diffusion
chambers.-The preparation, filling and im-
plantation of diffusion chambers for this
assay were identical to those previously
described for bone marrow cells (Gordon,
1974).
Pretreatment of mice before chamber im-
plantation.-Pretreatment of C57BL mice
used in these experiments was required before
implantation for successful growth ofcolonies
in the diffusion chambers (see Results
section). Standard pretreatment was with
whole-body irradiation from a 60Co source,
3 h before chamber implantation. When
900 rad whole-body irradiation was used,
following the technique employed with bone
marrow (Gordon et al., 1975), transplantation
ofthe chambers to newly irradiated mice was
required every ninth day, since this dose of
irradiation was usually fatal to the mice
around this time. Smaller doses of whole-
body irradiation were not usually fatal and
therefore did not require transplantation of
chambers.
It has been found by Dr John Millar,
working in this laboratory, that death after
900 rad or even 1000 rad whole-body irradi-
ation to C57BL mice can be prevented by
previous treatment with cytosine arabinoside
200 mg/kg i.p. between 1 and 3 days before
irradiation. Some chambers were therefore
implanted into C57BL mice treated with
cytosine arabinoside 200 mg/kg i.p. 48 h
before 1000 rad whole-body irradiation, and
in these animals transplantation was un-
necessary. In other experiments, the mice
were pretreated with cyclophosphamide 200
mg/kg i.p. 24 h before implantation instead
of whole-body irradiation, and this was well
tolerated.
In 2 experiments, chambers were im-
planted into thymectomized, whole-body
irradiated, marrow-reconstituted CBA/lac
mice (Pickard et al., 1975) or genetically
athymic nude mice, without irradiation or
other forms of pretreatment.
Colony counting.-Chamber-bearing n ice
were killed by cervical dislocation, and the
Millipore filter ofeach chamber removed with
a scalpel blade. Colonies were then counted
in the chamber under a binocular microscope
at a magnification of x 50. Colonies were
defined as aggregates of at least 50 cells, and
clusters as aggregates of between 20 and 50
cells. The optimum incubation period for
colony formation was determined by colony
counting at various times after implantation
until there was no further increase in colony
numbers.
RESULTS
Cell suspensions of all 11 human
tumour xenografts so far studied repro-
ducibly grew agar colonies in diffusion
chambers, and details of the incubation
period, the mean plating efficiency (PE),
and the number ofexperiments performed
for each xenograft are shown in the Table.
The incubation periods ranged from 12 to
28 days, but were fairly constant for each
tumour, and in general colonies from the
less differentiated tumours grew more
rapidly than those from more differenti-
ated ones. The mean PE of each tumour
was fairly constant, but the range between
tumours was from 0.3% to 16%.
There was variation in colony mor-
phology between different tumours: some
tumours produced colonies composed of
fairly loosely clumped cells (Fig. la) while
others produced densely packed spherical
colonies (Fig. lb), which in one tumour
(colonic carcinoma HX18) appeared to
develop a mucinous capsule, demonstrated
by Giemsa staining of a colony removed
from agar (Fig. Ic).- The morphology of
the colonies from each individual tumour
was the same on different occasions.
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K 32 Pancreatic carcinoma, Collagenase
anaplastic (Met)* +trypsin
K 18 Colonic adenocarcinoma,
poorly differentiated Trypsin
JR 5 Colonic carcimona,
anaplastic Trypsin
(K 1 Colonic adenocarcinoma,
mod. differentiated (Met) Trypsin
YK 9 Colonic adenocarcinoma,
poorlydifferentiated
(Met) Trypsin
i 12 Rectal adenocarcinoma,
well differentiated Trypsin
(K 4 Rectal adenocarcinoma
poorly differentiated Trypsin
i 29 Oat cell carcinoma of
lung (Met) PBSt
i 33 Oat cell carcinoma of
lung (Met) PBS
i 34 Melanoma (Met) PBS
C 35 Uterine carcinoma,
anaplastic (Met) PBS
* Met-Metastasis biopsy.




























































FIG. 1-(a) Typical agar colony from cells of colonic adenocarcinoma xenograft HXK1. x 350.
(b) Typical agarcolony from cells of colonic adenocarcinoma xenograft HX18. x 350. (c) Giemsa-
stained preparation of HX 18 colony removed from agar, showing mucinous capsule " leaking "
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The PE of colonies from each tumour
cell suspension depended greatly on the
pretreatment of the diffusion chamber
host mice. Details of the effects of
different pretreatment regimes on PE for
2 human tumour xenografts are shown in
Fig. 2. Diffusion chamber colonies did
not grow in untreated mice. Whole-body
60Co y-irradiation to the mice promoted
colony growth, and the PE increased
with increasing doses of irradiation.
Colonies grew as well in chambers main-
tained for 3 weeks in mice pretreated with
cytosine arabinoside 200 mg/kg and 1000
rad (preventing death of the mice) as in
chambers transplanted every ninth day
into mice pretreated with 900 rad alone.
Since the former technique saves mice
and labour, this has now been adopted as
standard pretreatment. Cyclophospha-
mide 200 mg/kg i.p., which has been
shown to be many times more effective
than other pretreatment schedules in





C22LR mouse osteosarcoma (Smink and
van Dierendonck, personal communica-
tion), was an ineffective pretreatment in
this system. PE was almost as high in
thymectomized, whole-body irradiated,
marrow-reconstituted CBA/lac mice as in
the 900-rad pretreated C57BL mice, while
chambers implanted into genetically athy-
mic " nude " mice produced the highest
PE of all. Practical factors prevented us
from using nude mice routinely for this
assay.
Chromosomal analyses of cell suspen-
sions from 6 of the xenografts have so far
been carried out, and these were all of
human karyotype. Four tumours had a
normal diploid chromosomal complement,
one (colonic carcinoma HX18) had an
added large acrocentric marker chromo-
some, and one (pancreatic carcinoma
HX32) showed aneuploidy, with a range
of 42 to 68 chromosomes and a mode of
62, with extra chromosomes coming from
groups C, D and E.
HX 18 (Colonic)





O rad 500 rad 700 rad 900 rad Ara-C Cyclophos- Thymecto- Nu
+ phamide mized
PRETREATMENT
1000 rad 200 mg/kg
Fio(. 2. The influence of different types of pretreatmeint on PE for 2 xenografts. The results for
each pretreatment are expressed as a percentage of the yield achieved using host, mice which had
received 900 ra(d whole-body irradiation (thymectomizecl an(I " nude " mice were riot used for
HX18 xenograft). Each pretreatment result is the mean of at least 3 experiments, except for














Fi(e. 3.---The relationship betwveen the iaunmber of colornies scored and the number of cells cultured
in agar (liffusion chambers for 2 xenografts. (a) Pancreatic xenograft HX 32; (b) Colonic xeno-
graft HX 18. Vertical bars represent ± s.e.
(iemsa-stained preparations of colo-
nies grown from colonic carcinoma HX18
showed undifferentiated neoplastic cells
with high nuclear cytoplasmic ratio, all
basically of the same type; comparison
with histological sections of the original
tumour xenograft showed that the colony
cells were entirely compatible with an
origin from that tumour (Dr A. Mackay,
Consultant Pathologist, Royal Marsden
Hospital).
A linear relationship between the
yield of colonies and the number of cells
introduced into the chambers was demon-
strated for the pancreatic tumour xeno-
graft HX32 over a range from 1 x 102 to
1'75 X 103 cells per chamber, and for the
colonic tumour HX18 over a range from
5 x 102 to 3 X 103 cells per chamber
(Fig. 3a and b).
The ability of this system to measure
the effect of cytotoxic drugs on PE of
human colonic carcinoma xenograft HX18
is shown in Fig. 4. In this example, in
vivo cyclophosphamide i.p. produced a
dose survival curve with a small range of
cell kill; the surviving fraction at the
maximum tolerated dose to the mouse
(300 mg/kg) was about 0-2.
D)ISCUSSION
Agar colony assays of human bone
marrow progenitor cells (Pike and Robin-
son, 1970; Gordon et al., 1975) and human
chronic granulocytic leukaemic cells



























Dose of cyclophosphamide (mg/kg)
FIG.4. The effect of in vivo cyclophosphamide on colony survival (colonic tumour HX18). Tumour
cell suspensions were matoe 18 h after i.p. injection. The surviving fraction was calculated as the
ratio ofthe PE ofthe treated cells to that ofthe controls. Each point represents the mean ofat least
5 chambers. Vertical bars represent ± s.e.
et al., 1971) are well established, and some
childhood solid tumours including neuro-
blastoma, hepatoblastoma, Wilms' tum-
our and rhabdosarcoma have occasionally
been shown to form colonies in agar
(McAllister and Reed, 1968; Sandor, 1973;
Altman et al., 1975). However, a repro-
ducible quantitative colony assay for
human solid tumours does not appear to
have been described. Practical diffi-
culties present a major obstacle: prelimi-
nary experiments suggest that cell suspen-
sions direct from human tumour biopsies
sometimes grow colonies in this system,
but it is usually impossible to obtain
repeated biopsies of the same human
tumour over the prolonged period neces-
sary to develop a reproducible assay.
This problem can to some extent be over-
come by the use of human tumour xeno-
grafts, which can provide a continuous
supply of tumour cells from which the
necessary criteria for colony growth can be
established. An important assumption
here is that biological characteristics
influencing xenograft response to therapy
do not alter with repeated passage: in this
laboratory no consistent major changes in
growth rate or histology of xenografts
have so far been demonstrated after the
initial passage from human to mouse
(Pickard et al., 1975) andreproducible dose
survival curves have been obtained using
the same treatment on different passages
ofxenografts over a period ofabout 1 year.
All 11 xenografts so far studied grew
colonies using agar in diffusion chambers
and chromosomal analysis and colony
cell morphology demonstrated that the
colonies were derived from human rather
than murine cell lines. Colonies from
each tumour had their own individual
incubation period and PE in this system,
however, and these parameters must
therefore be established empirically on an
individual basis for each tumour under
study.
Whether the effect of cytotoxic agents
on human tumour colony-forming cells
in agar correlates with clinical tumour
response is a question that has yet to be
answered. But the dose response to
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cyclophosphamide ofthe colonic carcinoma
HX18 (Fig. 4) offers some encouragement:
the sensitivity of this tumour is much less
than that established for experimental
animal tumours to cyclophosphamide
(Bruce, Meeker and Valeriote, 1966; Park
et al., 1971; Lin and Bruce, 1972; Ogawa,
Bergsagel and McCulloch 1973; Hill and
Stanley, 1975; Steel and Adams, 1975)
and this is consistent with the clinical
observation that human colonic carcino-
mas do not usually show a marked
response to cyclophosphamide. An in
vitro agar assay using the same xenograft
material has also recently been developed
in this laboratory, producing dose survival
curves which correlate closely with those
obtained by the diffusion chamber method
(V. D. Courtenay, in preparation). These
human tumour colony-forming assays may
therefore prove to be more realistic than
assays based on experimental animal
tumours for extrapolating laboratory
tumour response data to clinical cancer
therapy.
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